Evidence map›Paper›PMID 33496842›Full record

ReviewLung2021

COVID-19 in Children with Asthma.

Grigorios Chatziparasidis, Ahmad Kantar

Abstract readReview
In one paragraph

Review in Lung, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022
    Article
  9. Article
  10. Article
  11. Respiratory Symptoms, Allergies, and Environmental Exposures in Children with and without Asthma.International journal of environmental research and public health · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. COVID-19 in a group of children with asthma: presentation, severity, and outcome.American journal of clinical and experimental immunology · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Grigorios ChatziparasidisPrimary Cilia Dyskinesia Unit, School of Medicine, University of Thessaly, Thessaly, Greece. gchatziparasidis@gmail.com.ORCID http://orcid.org/0000-0003-4308-4710
Ahmad KantarPediatric Asthma and Cough Centre, Instituti Ospedalieri Bergamaschi, University and Research Hospitals, Bergamo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infects both children and adults but epidemiological and clinical data demonstrate that children are less likely to have a severe disease course or die. Furthermore, asthmatic children show less severe disease manifestations when infected with SARS-CoV-2 comparing to adults. This review focuses on SARS-CoV-2 and childhood asthma interaction and aims at summarizing the current knowledge of the potential mechanisms that ameliorate disease symptomatology in asthmatic children.

Indexed as

AsthmaAge FactorsAsymptomatic DiseasesChildCOVID-19FemaleHost-Pathogen InteractionsHumansMalePrognosisProtective FactorsRisk FactorsSARS-CoV-2Severity of Illness IndexAsthmaChildrenCOVID-19SARS-CoV-2

Identifiers

PMID33496842
PMCPMC7835665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.